Cell Analysis Market Assessment, By Product and Service [Consumables and Reagents, Instruments, Accessories, Software and Services], By Application [Oncology, Immunology, Cardiology, Genetic Disease, Stem Cells, Non-Invasive Prenatal Diagnosis, Others],

Cell Analysis Market Assessment, By Product and Service [Consumables and Reagents, Instruments, Accessories, Software and Services], By Application [Oncology, Immunology, Cardiology, Genetic Disease, Stem Cells, Non-Invasive Prenatal Diagnosis, Others], By Technique [Flow Cytometry, Mass Spectrometry, Next Generation Sequencing, Polymerase Chain Reaction, Others], By Process [Cell identification, Target Identification and Validation, Cell Interaction, Cell Viability, Others], By End-user [Academic and Research Laboratories, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Laboratories, Others], By Region, Opportunities and Forecast, 2017-2031F

Global cell analysis market is projected to witness a CAGR of 10.07% during the forecast period 2024-2031, growing from USD 22,708.17 million in 2023 to USD 48,913.48 million in 2031. The cell analysis market has witnessed significant growth driven by increasing demand for cell analysis tools in drug discovery and development, the development of advanced technologies such as automated cell counting, cell imaging, and flow cytometry, and the surge in R&D activities in the pharmaceutical and biotechnology industry. The cell analysis market is anticipated to thrive further and have a higher momentum during the forecast period.

Cell analysis identifies, measures, and studies different aspects of cell structure, function, and behavior. It can be used to detect disease and evaluate the effectiveness of treatments. The global cell analysis market is expected to grow further, supported by developments in biomedical research that offer detailed insights into cellular mechanisms, supporting drug discovery and development that prudently assess efficacy and toxicity, and enhancing clinical diagnostics by identifying disease markers.

The cell analysis market is experiencing rapid growth, further fueled by rising investments by biopharmaceutical companies, technological advancements, and a heightened demand for personalized medicine. For instance, in May 2024, Eli Lilly and Company announced an investment of USD 9 billion to increase production and manufacturing at their Indiana and Lebanon manufacturing sites. This aims to boost the manufacturing capacity of various APIs and pipeline medicine. This evolving sector includes diverse technologies such as high-throughput screening, single-cell analysis, flow cytometry, and advanced imaging techniques. Furthermore, new drug discovery plays a crucial role in keeping the market vibrant. For instance, in July 2024, the University of Oxford and Apollo Therapeutics Limited, a portfolio biopharmaceutical company, announced the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford.

Increasing Demand for Cell Analysis Tools in Drug Discovery Drives Market Growth

The increasing demand for cell analysis in drug discovery and development drives market growth. Advanced cell screening technologies enhance research by providing precise tools for target drug discovery and validation. These techniques provide accurate data on drug effects and cellular responses, speeding drug development and reducing costs. The search for new therapies drives continued innovation in cellular diagnostic tools. Strategically utilizing advanced cell analysis tools may be effective for enhancing pipeline investments and seizing future market opportunities. For instance, in June 2024, Becton, Dickinson and Company, a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell function and how it regulates changes in a cell that can lead to cancer and other diseases.

Development of Advanced Technologies Positively Impact Market Growth

Technological advancements are significantly boosting growth in the cell analysis market by enhancing research capabilities and broadening application areas. Key developments like high-throughput screening, flow cell measurements, and advanced imaging techniques are at the forefront of this transformation in cell analysis. The market is expanding rapidly as researchers and clinicians seek more accurate, efficient, and scalable solutions for studying cell biology, diagnosing diseases, and developing new treatments. This growth is further fueled by a combination of artificial intelligence and machine learning, which enhance advanced data analysis and interpretation. For instance, in July 2024, Agilent Technologies Inc. launched its novel ProteoAnalyzer system at the Singapore Cell and Gene Therapy Pan Asia Summit (SCGT). This system analyzes complex protein mixtures, facilitating quicker discoveries in pharmaceuticals, biopharma, and bioengineered food ingredients.

Prevalence of Oncological Disorders in the Global Cell Analysis Market

With the high prevalence of cancer, there is a substantial need for sophisticated diagnostic tests in the form of liquid biopsies and molecular profiling that are necessary to catch the disease early on with maximum accuracy. This demand drives the development and use of sophisticated cell analysis technologies. global preclinical data in oncology supports the utility of these platforms for evaluating drug efficacy and safety. CRISPR-based approaches, multiplex assays and a gamut of cutting-edge imaging techniques are advancing traditional technologies for cell demographics. These technologies are also applied to the clinic to track disease progression and customize patient care. Initial progress in spatial omics and real-time cellular assays also extends the dimensionality of cell analysis.

For instance, in July 2024, Moffitt Cancer Center received the U.S. FDA approval for lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy, which has shown promising results in treating various types of cancers, particularly melanoma and certain other solid tumors.

North America Dominates the Global Cell Analysis Market

North America holds the largest market share in the global cell analysis market. The region boasts a strong drug discovery ecosystem, quick adoption of cutting-edge technologies, and a high rate of chronic diseases, all of which fuel the demand for advanced cell analysis solutions. Moreover, the rising cases of cancer and substantial investments from both businesses and government organizations in cell-based research also contribute to the growth of the market. For instance, according to the National Cancer Institute, in 2024, an estimated 2 million new cancer cases will be diagnosed in the United States, with 611,720 people expected to die from the disease. By 2040, the number of new cancer cases is projected to rise to 29.9 million annually, and the number of cancer-related deaths is expected to reach 15.3 million.

Future Market Scenario (2024-2031F)

The incorporation of sophisticated fiber optics with microfluidic chips for single-cell analysis is a remarkable progression that will trigger growth in the coming years within this market. This technology improves the accuracy and effectiveness of single-cell research by allowing for direct µ-resolution inspection, images, and evaluation inside the microfluidic device. Thus, it enables the collection of detailed and accurate data about cellular properties within each cell, leading to insight into inter-cellular functions and heterogeneity.

Key Players Landscape and Outlook

The global cell analysis market is quite competitive with a huge number of players at local levels as well. Regulatory approvals of company products, mergers and acquisitions, and collaborations are the most common market strategies that have been observed in recent times.

In September 2023, Agilent Technologies Inc. established a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), to enhance cell and gene therapy over the next three years. This partnership will see the installation and use of Agilent’s extelligence real-time cell analyzer, Seahorse XF technology, and additional cell analysis tools at ACTRIS’s largest national facility focused on developing and manufacturing cell and gene therapy in Singapore.

In July 2024, Bio-RAD Laboratories, Inc. expanded its Pioneer Antibody Discovery Platform to include rapid generation and screening of bispecific antibodies using its proprietary SpyLock Technology. This enhancement enables customers to efficiently identify and develop effective antibody combinations.
"
"United States CT scanners market is projected to witness a CAGR of 5.16% during the forecast period 2024-2031, growing from USD 1,867.03 million in 2023 to USD 2,791.55 million in 2031. The market is mainly growing under the influence of the rising disease burden, technological advancements, growing emphasis on early cancer detection, and advanced healthcare services in the United States.

The tomographic images obtained from CT scanners are detailed and help healthcare professionals with proper diagnosis and treatment planning, making it vital during diagnosis. Advancements in imaging technology, rising expenditure in the health sector, and increasing demand for high-resolution diagnostic systems drive the growth of the United States CT scanners market. The advancements and innovations in the industry are expected to be influenced by multiple factors, such as the integration of artificial intelligence, enhancements in photon-counting detector technology, and an emphasis on personalized medicine. Additionally, the high incidence of diseases and the need for precise early diagnosis propels the growth of the CT scanners market in the United States. Also, healthcare policies focusing on improving patient outcomes and greater usage of mobile and portable CT scanners are shaping the market landscape. For instance, in June 2024, Rady Children's Hospital-San Diego introduced 3D Arc Viewer, a no-cost 3D model viewing software that enhances the utility of CT and MRI by providing direct, interactive access to sophisticated 3D reconstructions. This tool streamlines the process for surgeons by eliminating the need for radiology technologist assistance and allowing them to improve surgical planning. This can be attributed to the increasing demand for advanced imaging technologies and workflow efficiency improvement in clinical settings.

Rising Incidences of Cancer in the United States Promote Market Growth

The increasing burden of cancer cases in the United States has raised the demand for CT scanners in the region. Medical imaging modalities, such as CT and MRI scans, are crucial diagnostic tools in cancer detection as they precisely locate the tumors. CT scanners offer various advantages compared to other medical imaging modalities, mainly due to their strong sensitivity in the detection of minute tumors in the tissues. According to the World Health Organization (WHO), the number of newly diagnosed cancer cases in the United States is projected to increase from 2.38 million in 2022 to 3.38 million by 2045. This expected rise in new cases is likely to boost the market for computed tomography scanners in the United States, as rising rates of diagnoses of cancer are going to spur demand for faster, more accurate, and more comfortable imaging modalities. As per the data provided by WHO in 2022, lung cancer is the third most common cancer in the United States. The history of smoking represents the major risk factor for lung cancer. The younger population with smoking habits has a higher risk of developing lung cancer in their early lifetime. Accurate and effective management of lung cancer demands early disease diagnosis, which is possible through CT Chest imaging. Thus, the United States Preventive Services Task Force has recommended annual screenings for people at risk of developing lung cancer as a preventive measure. Such favorable regulations will further support the growth of the United States CT scanner market.

Advancements in Computed Tomography Supports Market Growth

The United States has been at the forefront of rapid R&D in medical imaging and thus remains in the leading position to advance healthcare. Dynamic advances within this field have transformed CT technology and greatly enhanced diagnostic capabilities, pushing the boundaries of what's possible. Key developments impacting the CT scanners market include the integration of AI functionality and the introduction of ultra-high-resolution CT scanners. For instance, in November 2023, Canon Medical Systems USA Inc. introduced its newest computed tomography scanners: the Aquilion ONE/INSIGHT Edition and the Aquilion Serve SP. Both systems boast the company's revolutionary INSTINX workflow and Advanced intelligent Clear-IQ Engine (AiCE) Deep Learning Technology. These upgrades aim to improve image quality, streamline operations continuously, and reduce the radiation dose for patients. Such advancements are leading to more distinct and superior-quality images, ultimately enhancing the effectiveness of clinical results and the quality of patient care.

High-Slice CT Scanners Segment is Expected to Account Major Market Share

In the technology segment, high-slice CT scanners are dominating the United States CT scanners market. Increasing demand for precision medicine and detailed scanning has led to a surge in demand for advanced imaging. Furthermore, as the healthcare framework and R&D continue to grow in the United States, there is an increasing demand for advanced technology and high-end systems. The rising demand for high-slice CT scanners by larger hospitals in the United States is due to the potential of their technology to streamline the workflow and improve patient outcomes. Additionally, the new launches and installations of high-end slice CT scanners in the United States are responsible for this segment's dominance in the United States market. The trend is also being propelled by a competitive market in which providers seek cutting-edge technologies to attract and retain patients. For instance, in November 2022, Fujifilm Holdings Corporation unveiled the SCENARIA View Focus Edition CT scanner at Radiological Society of North America (RSNA), which is setting new standards in the United States. This high-performance scanner is tailored for various applications, from coronary CT angiography to dual-energy exams, and possesses 64 detectors and 128-slice rotation capabilities. Its advanced features meet the basic and complex imaging requirements, driving its rapid adoption across healthcare facilities. The SCENARIA View's integration of sophisticated technology highlights its role as a leading solution in modern diagnostic imaging.

Future Market Scenario (2024-2031F)

Companies in the region are working on enhancing the technological aspects of CT scanners, which would further enhance medical imaging systems and diagnostics. The effort towards innovation will drive significant growth in the United States CT scanners market. For instance, in December 2023, Arineta Ltd. installed the SpotLight dedicated cardiovascular computed tomography scanner at Connected Cardiovascular Care Associates in Dallas, thereby marking a significant transition towards the focused approach of cardiovascular imaging in the United States market. The growing emphasis on advanced computed tomography technologies underpins better cardiovascular disease diagnosis. Their presence at major industry conferences further signals a growing demand for such targeted innovations in the CT scanner landscape. Moreover, Photon-counting technology is poised to revolutionize the United States CT scanners market, delivering double the resolution of conventional systems and spectral data in every scan. Photon-counting has gained some momentum in recent years as various major players, such as Siemens Healthineers AG, Samsung Neurologica Corporation, and GE HealthCare Technologies Inc., have increased R&D investments and research collaboration activities to deliver innovations in the photon-counting CT technology. It is highlighted in many sessions of the Radiological Society of North America (RSNA) that photon counting is projected to be the leading CT imaging technology in a decade and a driver of a shift in diagnostic imaging over the next.

Key Players Landscape and Outlook

Overall, the growth of the United States CT scanner market continues at an extremely high pace, driven by sizeable investments by major players in the introduction of novel diagnostic solutions. Collaboration agreements and the launch of new products further spur market development as companies expand their competencies in imaging. Such proactive approaches by key players underscore their commitment toward improvements in diagnosis and indirectly toward growing the market. The evolution of the technologies above gives a strong and dynamic view of the outlook of the CT scanner market in the United States.

In December 2023, Siemens Healthineers AG received FDA clearance for its air-cooled Somatom Pro.Pulse dual-source CT scanner. The compact and cost-effective model requires 31% less space while being more energy efficient. This innovation of Siemens Healthineers AG reflects the enhanced efficiency and economy in diagnostic imaging.

In July 2022, Canon Medical Systems USA Inc. expanded its presence in the United States by acquiring NXC Imaging to further expand its sales and service capabilities in the Upper Midwest. This strategic acquisition will allow Canon to enhance its regional reach and provide tailored imaging solutions, reflecting the company's further commitment to increasing its presence in the United States CT scanner market.